- $13.78m
- $12.15m
- $6.09m
- 90
- 78
- 53
- 86
Annual cashflow statement for PharmChem, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2002 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | PRESS | PRESS |
| Standards: | USG | USG | USG | — | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 3.34 | 1.85 | 0.87 | 0.845 | 1.38 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -4.35 | -0.123 | 0.116 | 0.09 | -0.163 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.091 | -0.687 | 0.143 | -0.278 | 0.066 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 1.34 | 0.875 | 1.27 | 0.639 | 1.31 |
| Capital Expenditures | -1.42 | — | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 9.96 | 0.02 | 0 | 0 | -0.003 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 8.54 | 0.02 | 0 | 0 | -0.003 |
| Financing Cash Flow Items | -1.99 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -5.87 | -6.51 | -0.2 | -2.35 | -1.25 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.02 | -5.62 | 1.07 | -1.71 | 0.057 |